{"entity":{"id":"traverse-biotech","kind":"company","name":"Traverse Biotech","aka":["TRAVERSE BIOTECH II INC","Traverse Biotechnology"],"tldr":"Traverse Biotech is a New York company that licenses immunotherapies already tested outside the United States and develops them further. Its lead product, TB-Bs1, is an antibody that links T cells to cancer cells carrying the protein ROR2.","summary":"Traverse Biotech, of New York City, describes itself as an immunotherapy company that acquires products built on clinically validated platforms under a risk-sharing model with the licensing partner. Its pipeline page names TB-Bs1, a CD3 by ROR2 DuoBody bispecific antibody for ROR2-positive solid tumours, as its lead product, alongside an innate immunity programme, an antibody-drug conjugate in an undisclosed indication and an in situ immunotherapy platform. In fiscal year 2026 the National Cancer Institute funded its SBIR project on a uPAR-targeting antibody-drug conjugate for pancreatic adenocarcinoma (1R43CA309866-01, USD 399,896).","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.traversebiotech.com/"},{"label":"Pipeline","url":"https://www.traversebiotech.com/pipeline-4-1"},{"label":"NIH RePORTER: 1R43CA309866-01","url":"https://reporter.nih.gov/project-details/11309753"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":["immunotherapy","adcs"],"technologies":["t-cell-engager","adc"],"targets":["cd3"],"drugs":["tb-bs1"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on traversebiotech.com (home and pipeline pages) and the NIH RePORTER record on 4 November 2026. The site does not say whether its undisclosed antibody-drug conjugate is the uPAR programme. No ROR2 target record exists in the corpus."],"hq":"New York, NY","country":"US","companyType":"biotech","website":"https://www.traversebiotech.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":399896,"source":"https://reporter.nih.gov/project-details/11309753","note":"NCI SBIR Phase I (R43) award 1R43CA309866-01: Development of a uPAR-Targeting Antibody-Drug Conjugate (ADC) for Pancreatic Adenocarcinoma"}]},"route":"/companies/traverse-biotech/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"drug":[{"id":"tb-bs1","kind":"drug","name":"TB-Bs1","route":"/drugs/tb-bs1/"}]}}